Adjuvant therapy for breast cancer

Annual Review of Medicine

Volumn 51, Issue , 2000, Pages 377-392

  Hortobagyi, G ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Chemotherapy; Hormonal therapy

Indexed keywords

ANTIESTROGEN; CYTOTOXIC AGENT; TAMOXIFEN;

ACUTE LEUKEMIA; ALOPECIA; ANEMIA; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CARDIOTOXICITY; CLINICAL TRIAL; COGNITIVE DEFECT; EARLY MENOPAUSE; FEMALE; HUMAN; META ANALYSIS; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; SEXUAL DYSFUNCTION; THROMBOCYTOPENIA; VOMITING;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; HUMANS; META-ANALYSIS; PROGNOSIS;

EID: 0034087716     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.51.1.377     Document Type: Review

References (66)

1. 1. Landis SH, Murray T, Bolden S, Wingo PA. 1999. Cancer statistics. Cancer J. Clin. 49:8-31
2. 2. Smart CR, Byrne C, Smith RA, et al. 1997. Twenty-year follow-up of the breast cancers diagnosed during the Breast Cancer Detection Demonstration Project. Cancer J. Clin. 47:134-49
3. 3. Morris AD, Morris RD, Wilson JF, et al. 1997. Breast-conserving therapy vs mastectomy in early-stage breast cancer: a meta-analysis of 10-year survival. Cancer J. 3:6-12
4. 4. Handel N. 1991. Current status of breast reconstruction after mastectomy. Oncology 5:73-89
5. 5. Fisher B. 1969. Systemic chemotherapy as an adjuvant to surgery in the treatment of breast cancer. Cancer 24:1286-89
6. 6. Hortobagyi GN. 1998. Treatment of breast cancer. N. Engl. J. Med. 339: 974-84
7. 7. Hortobagyi GN, Buzdar AU. 1995. Current status of adjuvant systemic therapy for primary breast cancer: progress and controversy. Cancer J. Clin. 45:199-226
8. 8. Early Breast Cancer Trialists' Collaborative Group. 1998. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351:1451-67
9. 9. Early Breast Cancer Trialists' Collaborative Group. 1998. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352:930-42
10. 10. Early Breast Cancer Trialists' Collaborative Group. 1992. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet 339:71-85
11. 11. Early Breast Cancer Trialists' Collaborative Group. 1992. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1-15
12. 12. Abeloff MD, Beveridge RA. 1988. Adjuvant chemotherapy of breast cancer - the Consensus Development Conference revisited. Oncology 2:21-29
13. 13. Glick JH, Gelber RD, Goldhirsch A, Senn HJ. 1992. Meeting highlights: adjuvant therapy for primary breast cancer. J. Natl. Cancer Inst. 84:1479-85
14. 14. Glick JH. 1988. Meeting highlights: adjuvant chemotherapy for breast cancer. J. Natl. Cancer Inst. 80:471-75
15. 15. Early Breast Cancer Trialists' Collaborative Group. 1996. Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet 348:1189-96
16. 16. Early Breast Cancer Trialists' Collaborative Group. 1995. Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. N. Engl. J. Med. 333:1444-55
17. 17. Bonadonna G, Zambetti M, Valagussa P. 1995. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. JAMA 273:542-47
18. 18. Norton L, Simon R. 1977. Tumor size, sensitivity to therapy and design of treatment schedules. Cancer Treat. Rep. 61: 1307-17
19. 19. Seidman AD. 1995. The emerging role of paclitaxel in breast cancer therapy. Clin. Cancer Res. 1:247-56
20. 20. Cortes JE, Pazdur R. 1995. Docetaxel. J. Clin. Oncol. 13:2643-55
21. 21. Henderson IC, Berry D, Demetri G, et al. 1998. Improved disease-free (DSF) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (PTS) with node-positive primary breast cancer (BC). Proc. Am. Soc. Clin. Oncol. 17:101a (Abstr.)
22. 22. Hryniuk WM, Bush H. 1984. The importance of dose intensity in chemotherapy of metastatic breast cancer. J. Clin. Oncol. 2:1281-88
23. 23. Frei EI. 1966. Selected considerations regarding chemotherapy as adjuvant in cancer treatment. Cancer Chemother. Rep. 50:1-8
24. 24. Frei EI, Antman K, Teicher B, et al. 1989. Bone marrow autotransplantation for solid tumors - prospects. J. Clin. Oncol. 7:515-26
25. 25. Hortobagyi GN. 1995. Are the results of high-dose chemotherapy in breast cancer really better than standard treatment? Bone Marrow Transplant. 15:S260-64
26. 26. Rahman ZU, Hortobagyi GN, Buzdar AU, Champlin R. 1998. High-dose chemotherapy with autologous stem cell support in patients with breast cancer. Cancer Treat. Rev. 24:249-63
27. 27. Antman KH. Dose-intensive therapy in breast cancer. 1992. In High-Dose Cancer Therapy, ed. JO Armitage, KH Antman, pp. 701-18. Baltimore: Williams & Wilkins. 1st ed.
28. 28. Antman KH, Rowlings PA, Vaughan WP, et al. 1997. High-dose chemotherapy with autologous hematopoietic stemcell support for breast cancer in North America. J. Clin. Oncol. 15:1870-79
29. 29. Rahman ZU, Frye DK, Buzdar AU, et al. 1997. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. J. Clin. Oncol. 15:3171-77
30. 30. Hortobagyi GN, Buzdar AU, Champlin R, et al. 1998. Lack of efficacy of adjuvant high-dose (HD) tandem combination chemotherapy (CT) for high-risk primary breast cancer (HRPBC) - a randomized trial. Proc. Am. Soc. Clin. Oncol. 17:123a (Abstr.)
31. 31. Rodenhuis S, Richel DJ, van der Wall E, et al. 1998. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymphnode involvement. Lancet 352:515-21
32. 32. Peters W, Rosner G, Vredenburgh J, et al. 1999. A prospective, randomized comparison of two doses of combination alkylating agents as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes: preliminary results of CALGB 9082/SWOG 9114/NCIC MA-13. Proc. Am. Soc. Clin. Oncol. 18:1a (Abstr.)
33. 33. The Scandinavian Breast Cancer Study Group 9401. 1999. Results from a randomized adjuvant breast cancer study with high dose chemotherapy with CTCb supported by autologous bone marrow stem cells versus dose escalated and tailored FEC therapy. Proc. Am. Soc. Clin. Oncol. 18:2a (Abstr.)
34. 34. Bezwoda WR. 1999. Randomized, controlled trial of high dose chemotherapy versus standard dose chemotherapy for high risk, surgically treated, primary breast cancer. Proc. Am. Soc. Clin. Oncol. 18:2a (Abstr.)
35. 35. Buzdar AU, Hortobagyi G. 1998. Update on endocrine therapy for breast cancer. Clin. Cancer Res. 4:527-34
36. 36. DeCillis A, Anderson S, Bryant J, Wickerham DL, Fisher B, 1997. Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) on NSABP B-25: an update. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 16:A459 (Abstr.)
37. 37. Diamandidou E, Buzdar AU, Smith TL, et al. 1996. Treatment-related leukemia in breast cancer patients treated with fluorouracil - doxorubicin - cyclophosphamide combination adjuvant chemotherapy: the University of Texas M.D. Anderson Cancer Center experience. J. Clin. Oncol. 14:2722-30
38. 38. Tallman MS, Gray R, Bennett JM, et al. 1995. Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: the Eastern Cooperative Oncology Group experience. J. Clin. Oncol. 13:1557-63
39. 39. Curtis RE, Boice JD Jr, Stovall M, et al. 1992. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N. Engl. J. Med. 326:1745-51
40. 40. Del Mastro L, Venturini M, Sertoli MR, Rosso R. 1997. Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications. Breast Cancer Res. Treat. 43:183-90
41. 41. Bines J, Oleske DM, Cobleigh MA. 1996. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J. Clin. Oncol. 14:1718-29
42. 42. Ganz PA. 1998. Cognitive dysfunction following adjuvant treatment of breast cancer: a new dose-limiting toxic effect? J. Natl. Cancer Inst. 90:182-83
43. 43. Ganz PA, Rowland JH, Desmond K, et al. 1998. Life after breast cancer: understanding women's health-related quality of life and sexual functioning. J. Clin. Oncol. 16:501-14
44. 44. Buzdar AU, Hortobagyi GN, Singletary SE, et al. 1997. Impact of FAC-adjuvant therapy on mortality of early breast cancer: long-term results of the M.D. Anderson Cancer Center studies. In Adjuvant Therapy of Cancer VIII, ed. SE Salmon, pp. 93-100. Philadelphia: Lippincott-Raven
45. 45. Hortobagyi GN, Buzdar AU. 1993. Present status of anthracyclines in the adjuvant treatment of breast cancer. Drugs 45(Suppl. 2):10-19
46. 46. Fleisch H. 1997. Bisphosphonates: mechanisms of action and clinical use in osteoporosis - an update. Horm. Metab. Res. 29:145-50
47. 47. Powles TJ, McCloskey E, Paterson AH, et al. 1998. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J. Natl. Cancer Inst. 90:704-8
48. 48. Love RR, Newcomb PA, Wiebe DA, et al. 1990. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J. Natl. Cancer Inst. 82:1327-32
49. 49. Saarto T, Blomqvist C, Ehnholm C, et al. 1996. Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer. J. Clin. Oncol. 14:429-33
50. 50. Rutqvist LE, Mattsson A. 1993. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. J. Natl. Cancer Inst. 85:1398-1406
51. 51. Cohen CJ. 1997. Tamoxifen and endometrial cancer: tamoxifen effects on the human female genital tract. Semin. Oncol. 24:S155-64
52. 52. Fisher B, Costantino JP, Redmond CK, et al. 1994. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl. Cancer Inst. 86: 527-37
53. 53. Dhingra K, Hortobagyi GN. 1996. Critical evaluation of prognostic factors. Semin. Oncol. 23:436-45
54. 54. Ravdin PM. 1997. Prognostic factors in breast cancer. ASCO Education Book, Spring 1997, pp. 217-27. Alexandria, VA: Am. Soc. Clin. Oncol.
55. 55. Goldhirsch A, Glick JH, Gelber RD, Senn HJ. 1998. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J. Natl. Cancer Inst. 90:1601-8
56. 56. Hortobagyi GN, Singletary SE, McNeese MD. 1996. Treatment of locally advanced and inflammatory breast cancer. In Diseases of the Breast, ed. JR Harris, ME Lippman, M Morrow, S Hellman, pp. 585-99. Philadelphia: Lippincott-Raven. 1st ed.
57. 57. Hortobagyi GN, Buzdar AU. 1991. Locally advanced breast cancer: a review including the M.D. Anderson experience. In High-Risk Breast Cancer, ed. J Ragaz, IM Ariel, pp. 382-415. Berlin: Springer-Verlag, 1st ed.
58. 58. Hortobagyi GN. 1994. Multidisciplinary management of advanced primary and metastatic breast cancer. Cancer 74(Suppl.):416-23
59. 59. Valagussa P, Zambetti M, Bonadonna G, et al. 1990. Prognostic factors in locally advanced noninflammatory breast cancer. Long-term results following primary chemotherapy. Breast Cancer Res. Treat. 15:137-47
60. 60. Recht A, Bartelink H, Fourquet A, et al. 1998. Postmastectomy radiotherapy: questions for the twenty-first century. J. Clin. Oncol. 16:2886-89
61. 61. Overgaard M, Hansen PS, Overgaard J, et al. 1997. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N. Engl. J. Med. 337:949-55
62. 62. Ragaz J, Jackson SM, Le N, et al. 1997. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N. Engl. J. Med. 337:956-62
63. 63. Cuzick J, Stewart H, Peto R, et al. 1987. Overview of randomized trials of post-operative adjuvant radiotherapy in breast cancer. Cancer Treat. Rep. 71:15-29
64. 64. Cuzick J, Stewart H, Rutqvist L, et al. 1994. Cause-specific mortality in longterm survivors of breast cancer who participated in trials of radiotherapy. J. Clin. Oncol. 12:447-53
65. 65. Hellman S. 1997. Stopping metastases at their source [editorial]. N. Engl. J. Med. 337:996-97
66. 66. Perloff M, Norton L, Korzun AH, et al. 1996. Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: a cancer and leukemia group B study. J. Clin. Oncol. 14: 1589-98